Scientific Progress in Feline HCM
Why Advancements Matter
Breakthroughs in veterinary cardiology are bringing new hope to cats living with hypertrophic cardiomyopathy (HCM). Researchers and clinicians continue to work tirelessly to better understand this complex disease, and launch new therapies.
For years, treatment has been limited to symptom management and supportive care. With scientific advancements the landscape is shifting toward earlier intervention, more precise treatment options, and a stronger foundation for long-term health and quality of life.
We are witnessing a new era of understanding and action in feline HCM!
The HALT HCM Study
One of the most impactful research efforts in recent years has been the HALT HCM Study (Hypertrophic Cardiomyopathy: Assessment of Long-Term Therapy). This multicenter, long-term clinical trial evaluates potential treatments aimed at slowing or halting the progression of feline HCM.
Key goals of the HALT study include:
- Identifying therapies that reduce heart muscle thickening
- Improving quality of life and long-term outcomes for affected cats
- Collecting robust data to support evidence-based treatment protocols
The HALT study has brought unprecedented collaboration between academic institutions, veterinary cardiologists, and industry partners, and the findings are informing new approaches to care.
Introducing Felicyn: New Chapter in Feline HCM Treatment
In August 2025, a novel drug therapy called Felicyn is launching, offering the first targeted medical treatment specifically approved for use in cats with HCM.
Felicyn is designed to:
- Reduce cardiac muscle stiffness
- Improve blood flow and cardiac function
- Delay the progression of clinical symptoms
Developed based on the latest research and trial data, Felicyn represents a major advancement in feline heart care and brings new optimism to caregivers and veterinary professionals alike.